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AbsTrACT
Artemether–lumefantrine (AL) and artesunate–amodiaquine 
(AS-AQ) are the most commonly used artemisinin-based 
combination therapies (ACT) for treatment of Plasmodium 
falciparum in Africa. Both treatments remain efficacious, but 
single nucleotide polymorphisms (SNPs) in the Plasmodium 
falciparum multidrug resistance 1 (Pfmdr1) gene may 
compromise sensitivity. AL and AS-AQ exert opposing selective 
pressures: parasites with genotype 86Y, Y184 and 1246Y are 
partially resistant to AS-AQ treatment, while N86, 184 F and 
D1246 are favoured by AL treatment. Through a systematic 
review, we identified 397 surveys measuring the prevalence 
of Pfmdr1 polymorphisms at positions 86 184 or 1246 in 
30 countries in Africa. Temporal trends in SNP frequencies 
after introduction of AL or AS-AQ as first-line treatment were 
analysed in 32 locations, and selection coefficients estimated. 
We examined associations between antimalarial policies, 
consumption, transmission intensity and rate of SNP selection. 
1246Y frequency decreased on average more rapidly in 
locations where national policy recommended AL (median 
selection coefficient(s) of −0.083), compared with policies of 
AS-AQ or both AL and AS-AQ (median s=−0.035 and 0.021, 
p<0.001 respectively). 86Y frequency declined markedly after 
ACT policy introduction, with a borderline significant trend for 
a more rapid decline in countries with AL policies (p=0.055). 
However, these trends could also be explained by a difference 
in initial SNP frequencies at the time of ACT introduction. 
There were non-significant trends for faster selection of N86 
and D1246 in areas with higher AL consumption and no 
trend with transmission intensity. Recorded consumption of 
AS-AQ was low in the locations and times Pfmdr1 data were 
collected. SNP trends in countries with AL policies suggest a 
broad increase in sensitivity of parasites to AS-AQ, by 7–10 
years after AL introduction. Observed rates of selection have 
implications for planning strategies to cycle drugs or use 
multiple first-line therapies to maintain drug efficacy.
InTroduCTIon
For many years, the recommended first-line 
treatment for uncomplicated Plasmodium 
falciparum malaria was chloroquine but resist-
ance emerged in South East Asia and South 
America in the 1950s, subsequently spreading 
through Africa in the 1970s–1980s.1 As 
a consequence, many African countries 
changed policy for treatment of uncom-
plicated falciparum malaria to recommend 
Key questions
What is already known?
 ► The two antimalarial drugs most commonly used in 
sub-Saharan Africa, artemether–lumefantrine (AL) 
and artesunate–amodiaquine (AS-AQ), exhibit col-
lateral sensitivity.
 ► Parasites with the YYY haplotype at positions 86, 184 
and 1246 in the multidrug resistance transporter 1 
(Pfmdr1) gene show reduced sensitivity to AS-AQ, 
while the NFD haplotype is associated with reduced 
sensitivity to AL.
What are the new findings?
 ► We find a widespread decline in the prevalence of 
the 86Y and 1246Y mutations, particularly in coun-
tries which recommended AL as first-line antima-
larial treatment over the last ~10 years, suggesting 
slightly increased sensitivity to AS-AQ and slightly 
reduced sensitivity to AL.
 ► Different artemisinin-based combination therapies 
(ACT) first-line policies and historical frequencies of 
the mutations are significantly associated with rates 
of selection, but malaria transmission intensity is 
not.
What do the new findings imply?
 ► The observed rates of selection have implications 
for designing policies which exploit the collateral 
sensitivity of these two drugs, such as drug cycling, 
sequential ACT treatments or multiple first-line 
therapies.
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sulphadoxine–pyrimethamine (SP) instead. However, 
increasing clinical SP treatment failures in the late 1990s, 
particularly in East Africa, demanded a change in policy. 
Since 2001, WHO has recommended treating uncompli-
cated malaria with artemisinin-based combination ther-
apies (ACTs), which are now adopted as policy in nearly 
all endemic countries.2 ACTs consist of a fast-acting arte-
misinin derivative that quickly reduces the parasite load, 
combined with a partner drug with a much longer half-
life (eg, lumefantrine, amodiaquine, mefloquine, piper-
aquine) that will eliminate the remaining parasites and 
protect against the establishment of new infections for a 
period of time postprime infection.3 4 However, there is 
evidence of emerging artemisinin resistance in South-East 
Asia, shown by decreasing parasite clearance rates after 
treatment and also, increasingly, ACT treatment failure 
in areas where partner drug resistance has spread.5 6 
Single nucleotide polymorphisms (SNPs) in the P. falci-
parum kelch 13 gene are associated with reduced suscep-
tibility to artemisinin in vivo and in vitro.7 8 Although it 
has not yet been documented that such parasites occur 
in Africa, recent data from a few African countries show 
diminished efficacy of certain ACT combinations,9 10 
thus, other P. falciparum genes may also be involved in 
ACT resistance.
Artemether–lumefantrine (AL) and artesunate–
amodiaquine (AS-AQ) are by far the most commonly 
used ACTs in Africa,2 although access to these treatments 
still remains relatively low in many areas.11 Interestingly, 
these two drugs appear to exert opposing selection pres-
sures on polymorphisms in the P. falciparum multidrug 
resistance transporter 1 (Pfmdr1) gene, which codes 
for transporter molecule P-glycoprotein homologue 1. 
Mutations in Pfmdr1 were first shown to be important 
in chloroquine resistance12 and they have since been 
shown to have significant effects on tolerance and resis-
tance to most other antimalarial drugs.13–17 In Africa, 
SNPs in codons N86Y, Y184F and D1246Y of Pfmdr1 are 
most common and different haplotype combinations of 
these confer reduced sensitivity to different drugs. For 
instance, AQ alone and AS-AQ have been shown to select 
for Pfmdr1 86Y, Y184 and 1246Y (the YYY haplotype) while 
the AL combination selects for N86, 184F and D1246 
(the NFD haplotype).5 18–22 Similar observations have 
been documented in in vitro and ex vivo susceptibility 
assays.23–25 A meta-analysis estimated that parasites with 
the N86 wildtype genotype are 4.7 times more likely to 
recrudesce after AL treatment than parasites with the 86Y 
genotype.5 In addition, early treatment failures that occur 
between day 2 and 3 post-treatment with AL and also 
another ACT, dihydroartemisinin (DHA)–piperaquine, 
were significantly associated with the Pfmdr1 NFD haplo-
type in a study in Kenya.26 27 A recent study from Tanzania 
on reinfection post-treatment estimated that parasites 
harbouring the Pfmdr1 NFD haplotype were able to with-
stand a 15-fold higher concentration of lumefantrine 
compared with parasites with the Pfmdr1 YYY haplotype.27 
The effect of the artemisinin component on selection 
is less clear. Gene editing suggests that Pfmdr1 86Y may 
increase parasite susceptibility to DHA, the active metab-
olite of artemisinin derivatives, although this only occurs 
in standard parasite growth inhibition experiments and 
not after the 6-hour DHA exposure assay which is more 
representative of exposure in vivo.13 Pfmdr1 copy number 
variation is also associated with differential susceptibility 
to antimalarials, with multiple copies reducing sensitivity 
to lumefantrine and mefloquine. In Africa, multiple 
copies are rare in most surveys, with a few exceptions, 
notably a recent study in Ethiopia.28
The observed opposing selection pressure of AL and 
AS-AQ has led to interest in harnessing this effect to 
optimise malaria treatment efficacy. For instance, these 
two drugs could be cycled in national treatment poli-
cies,29 deployed simultaneously in populations30 or used 
sequentially in individual patients when the initial treat-
ment fails.31 Planning for these strategies will benefit from 
understanding and quantifying the current direction and 
rates of change in these SNPs in populations in relation 
to ACT policies and consumption. Here, we collate and 
map all published Pfmdr1 SNP data at positions 86, 184 
and 1246 and analyse the effect of implementation of 
AS-AQ and AL on the temporal trends in the population 
prevalence of these SNPs across Africa.
MeTHods
systematic review
A PubMed Search was carried out up to the 20 October 
2017 using the following free text and MESH words: 
“Plasmodium falciparum”[Mesh] OR Plasmodium falci-
parum[Text Word]))) AND ((Malaria[Text Word] OR 
“Malaria”[Mesh] OR “Malaria, falciparum”[Mesh]))) 
AND (((single nucleotide polymorphisms[Text Word] 
OR “Polymorphism, Single Nucleotide”[Mesh] OR “mdr 
gene protein, Plasmodium” OR multidrug resistance 
gene* OR genetic variant* OR Plasmodium falciparum 
Polymorphisms[text word] OR Pfmdr*. The bibliogra-
phies of the articles were read to identify more relevant 
studies. We included studies published after 1990 which 
measured the prevalence of the Pfmdr1 N86Y, Y184F or 
D1246Y in samples from African countries which reported 
the year of data collection. We excluded articles based on 
in vitro studies or case reports, or where samples had been 
collected post-treatment. When samples were collected 
over more than a year, and the data were not disaggre-
gated, the year was set to the midpoint of the study years. 
Towards the end of our review, data from an independent 
review were made available on the Worldwide Antima-
larial Resistance Network (WWARN) website.32 We cross-
checked our data and used an additional variable avail-
able in the WWARN database: the proportion of samples 
containing mixed wild type and resistant parasites.
data on antimalarial policies and antimalarial consumption
Data on antimalarial drug policies by country and year 
were extracted from annual World Malaria Reports by 
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the WHO33 back to 2008, and WHO country reports prior 
to this time.34 In some areas, there were delays between 
policy change and implementation,35 36 but we used the 
official date of policy introduction recorded by WHO for 
all countries for consistency. We categorised country first-
line treatment policies at the time the Pfmdr1 SNP data 
were collected as AL alone, AS-AQ alone or both AL and 
AS-AQ (the latter means that patients are given either AL 
or AS-AQ—from here on, we call this policy AL/AS-AQ). 
Countries were included in the analysis if they had had a 
consistent first-line ACT policy for at least 5 years and for 
longer than any other ACT policy.
Data on reported antimalarial drug consumption 
in children from 0 to 5 years old were obtained from 
Demographic and Health Surveys (DHS), Malaria Indi-
cator Surveys (MIS)37 and Multiple Indicator Cluster 
surveys (MICS, Unicef) carried out from 1999 to the 
present.38 We summarised data at the national level, 
allowing for the weighted, stratified survey designs. We 
also used the estimated percent of febrile, rapid-diag-
nostic-test (RDT) positive 0–5-year-old children treated 
with ACT, by country and year that were recently released 
by the Malaria Atlas Project.11 These estimates take into 
account country-specific ACT procurement data as well 
as reported use during DHS, MIS and MICS surveys. For 
a further source of estimates of ACT consumption, we 
used data on the market share of different types of anti-
malarials measured by ACTWatch in national surveys, 
where ‘% market share’ is defined as “% adult equiva-
lent treatment dosages of a given type of antimalarial, out 
of the total sold or distributed in the previous week’.39 
ACTWatch surveyed a representative sample of both 
public and private outlets providing or selling antimalar-
ials. Some surveys recorded the use of ACT but did not 
specify a type. Here, we assumed that the ACT taken was 
the first-line antimalarial in the country policy at the time 
if their policy contained only a single ACT and excluded 
these data if the country policy recommended more than 
one first-line ACT.
statistical analysis
Pfmdr1 mutation prevalence data were geolocated and 
mapped using the maptools package in R software 
V.3.4.0.40 We analysed the rate and direction of selec-
tion before and after changing to ACT policy for each 
country and location, including locations which had two 
or more measures of a mutation (at least one non-zero) 
at different time points spanning at least 3 years during 
either the pre-ACT or post-ACT policy time periods. We 
grouped locations that were within 50 km of each other, 
with the exception of western Kenya, where some meas-
ures 100 km apart were aggregated in the published data, 
and therefore all data from this region were grouped. 
For these time series data, we extracted not only the 
prevalence of the mutations in infected individuals but 
also the frequencies of mutations in the parasite popula-
tion reported by the original studies where available. For 
example, some simply exclude mixed wild type-resistant 
infections, or assume that these infections contain one 
wild type and one resistant parasite clone, or use statistical 
methods to estimate frequencies. Otherwise, frequen-
cies of mutations were estimated where possible using 
a previously published method.41 This method requires 
an estimate of local slide prevalence in order to estimate 
the distribution of the number of parasite clones per 
infected person. We used the Malaria Atlas Project esti-
mates of slide prevalence in the year and location that 
each study was done, within a 20 km radius of the study 
location.42 Frequency estimation using this previously 
published method has been found to be robust as long as 
the proportion of mixed wild type-resistant infections is 
known,41 and therefore, we did not estimate frequencies 
for studies not reporting these data.
Selection coefficients (the % change in relative 
frequency of the mutant genotype per parasite genera-
tion) were calculated for each mutation at each location, 
by linear regression of the log ratio of mutant to wild 
type frequency over time.43 44 We assumed three para-
site generations per year.45 The regression was weighted 
by the inverse variance of the log frequency ratio from 
each survey, to allow for different sample sizes. We also 
computed selection coefficients using prevalence of 
mutation data in individuals instead of frequency in 
parasites, for comparison and found this made very little 
difference in the large majority of locations (n=20 loca-
tions with both frequency and prevalence data, online 
supplementary information). Therefore, in locations 
where frequency data were not available, we used prev-
alence data instead to compute selection coefficients 
(n=12 locations). We allowed selection coefficients to be 
different during pre-ACT versus post-ACT periods but 
otherwise assumed constant selection over time in each 
location. To test for a difference in mean selection coef-
ficients according to different potential drivers of selec-
tion, we used a multilevel model with random intercepts 
and slopes for each location46 47 and tested for a differ-
ence in slopes in areas with different covariate categories 
using interaction terms. Due to small numbers of coun-
tries with AS-AQ policies, we grouped these together with 
countries using both AL/AS-AQ for some analyses. Other 
covariates tested were the initial frequency/prevalence of 
the SNP at the start of the time series, antimalarial use 
(ACT use estimated by the Malaria Atlas Project, chloro-
quine use estimates from DHS, MIS and MICS surveys) 
and transmission intensity (measured by slide prevalence 
in 2–10 year olds.42 Antimalarial use and slide preva-
lence for each location were computed as the mean of all 
data points/estimates measured during the time period 
where a SNP time series was available, and for antima-
larial use, we also included any measures within 2 years of 
the start and end of the time period, because there were 
often several years between surveys. The only exception 
was chloroquine use in Rwanda, which was most recently 
measured as zero in 2005. We also assumed zero use 
during later years, since it is unlikely that chloroquine 
use would have increased after 2005.
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Figure 1 Prevalence of the 86Y, 1246Y and 184F Plasmodium falciparum multidrug resistance 1 (Pfmdr1) mutants in infected 
individuals in Africa over different time periods. Prevalences before 2004 are shown in online supplementary figure S1.
resulTs
systematic review results
The literature search identified 930 articles, of which 171 
met the inclusion criteria. Data were extracted from 397 
surveys measuring the prevalence or frequency of at least 
one Pfmdr1 polymorphism in 30 countries published up 
to October 2017. There were 397 214 and 211 surveys 
measuring the 86Y, 184F and 1246Y mutations, respec-
tively, and we obtained mutation frequency estimates for 
229, 129 and 146 surveys (figure 1, online supplementary 
figure 1, online supplementary data). The number and 
time points of surveys varied greatly between locations, 
with sparser coverage in parts of central Africa. The 86Y 
and 184F mutations are ubiquitous, but higher levels of 
86Y were more often recorded in East and Central Africa 
compared with West Africa during the 1990s and early 
2000s, whereas West Africa tended to have higher levels 
of 184F (figure 2A,B). The 1246Y mutation occurred on 
average at lower levels than the other two Pfmdr1 poly-
morphisms and was not detected at all in 17% of surveys. 
The 1246Y is found in all regions of the continent, but 
higher prevalences of the mutation were detected mainly 
in East Africa (figure 2C), with a prevalence of 1246Y 
of over 50% only being detected in Kenya, Uganda and 
Tanzania.
Quantifying snP selection over time by ACT policy
Figure 3 shows data on the three Pfmdr1 mutations over 
time in locations which had multiple measures over at 
least 3 years, after introduction of ACT policy (n=177 
surveys). Additionally, online supplementary figure S2-7 
show each location separately. Each location was catego-
rised according to whether the country had a first-line 
policy of treating all patients with AL, all with AS-AQ, 
or patients with either AL or AS-AQ (the latter policy is 
referred to as AL/AS-AQ) (figure 3, online supplemen-
tary figure S3 and 8). The full data across the continent 
suggest a marked decline in the frequency/prevalence of 
the 86Y mutant after about 2005 (figure 2A), and this was 
confirmed in 32 locations (15 countries) with longitudinal 
data after ACT introduction, where 30 of the 32 locations 
observed a decline in 86Y (figure 3A–C). The decline was 
on average fastest in locations within countries which had 
a policy of AL as first line treatment (n=16), with a median 
selection coefficient of −0.096 (figure 3A–C). However, 
the decline was also observed in locations within coun-
tries with AS-AQ (n=4) or AL/AS-AQ policies (n=12), 
with median selection coefficients of −0.068 and −0.070, 
respectively (borderline statistically significant difference 
from AL countries, p=0.055, online supplementary table 
S1). However, higher initial 86Y frequencies at the start 
of the observed time period were significantly associated 
with a more rapid decline over time (p<0.001) (figure 2, 
online supplementary figure S2 and 9 & table S1) and 
were on average different in countries with different ACT 
policies. After adjusting for this variable, countries with 
AL policy still had more rapid declines in 86Y frequency, 
but the difference was reduced and was not statistically 
significant (p=0.32).
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Figure 2 The frequency or prevalence of Plasmodium falciparum multidrug resistance 1 (Pfmdr1) mutations over time. Where 
possible, mutant frequencies were extracted from publications or estimated (see the Methods section), otherwise mutant 
prevalence data are shown. Locations are coloured by geographical region and include the following countries. East Africa: 
Uganda, Tanzania, Zanzibar, Tanzania, mainland, Swaziland, Sudan, Rwanda, Mozambique, Malawi, Madagascar, Kenya, 
Ethiopia, Eritrea, Comoros; West Africa: Senegal, Nigeria, Mauritania, Mali, Liberia, Guinea-Bissau, Ghana, Gambia, Burkina 
Faso, Benin; Central Africa: Sao Tome and Principe, Republic of Congo, Gabon, Equatorial Guinea, Democratic Republic of 
Congo, Central African Republic, Cameroon, Angola. See also online supplementary figure S2-4 for the data separately by 
location and online supplementary data for the full data.
By contrast, the 184F mutation increased in frequency/
prevalence in 13 out of 20 locations with available data: 
these included countries in East Africa as well as parts 
of Ghana and Senegal (figure 3, online supplementary 
figure S6). In countries with AL as first-line policy, the 
median selection coefficient for the mutant was highest 
at 0.051 per generation, while in countries with AS-AQ 
(data only available from Tanzania, Zanzibar for this 
mutant) or AL and AS-AQ policy, the median selection 
coefficients were 0.011 and 0.023, respectively. This 
difference between selection coefficients in countries 
recommending AL versus AS-AQ or AL/AS-AQ was not 
statistically significant (p=0.280, online supplementary 
table S1).
1246Y mutant frequency/prevalence decreased in 
most locations within countries with AL policies (8 out 
of 9) (figures 2C and 3G) but showed more variable 
patterns in areas recommending AL/AS-AQ or AS-AQ 
alone (figures 2C, 3H and I). The most rapid selection 
of the wild type D1246 occurred mainly in East African 
countries (Kenya, Tanzania, Uganda) but also in parts of 
Ghana (online supplementary figure S4). The median 
selection coefficient of 1246Y in areas with AL policy was 
−0.083 (n=9), but in areas recommending AL/AS-AQ or 
AS-AQ alone (n=8 and 3, respectively), the trends were 
on average more stable, with median selection coeffi-
cients of −0.035 and 0.021, respectively (a statistically 
significant difference between selection coefficients in 
AL versus AS-AQ or AL/AS-AQ countries, p<0.001, online 
supplementary table S1). However, again the difference 
could be explained by different initial frequencies as well 
as by different drug policies. Mutant 1246Y was signifi-
cantly higher at the time of ACT introduction in loca-
tions within countries which chose AL compared with the 
other policy options (p=0.004 figure 3G–I), and its initial 
frequency was also significantly negatively associated with 
the subsequent selection (p<0.001 online supplementary 
figure S9). After adjusting for starting frequency, there 
was no significant effect of drug policy on selection coef-
ficients (p=0.66).
snP selection before introducing ACT policy
Before ACTs were introduced as first-line policy, trends in 
the 86Y mutation were variable but remained at relatively 
stable levels in most locations with available data (n=16, 
median selection coefficient −0.006, online supplemen-
tary figure S10). Few locations had available data on 
184F and 1246Y frequencies before ACT introduction, 
precluding further analysis (online supplementary figure 
S11 and S12).
Quantifying snP selection over time by ACT and chloroquine 
consumption and transmission intensity
DHS and MIS surveys show the changing types of antima-
larial drugs used over time in 0–5 year olds, with a clear 
scale up in access to ACTs in many countries. Figure 4 
shows ACT consumption data from countries with 
available Pfmdr1 SNP data and different ACT first-line 
policies. The change in ACT consumption occurred at 
variable rates in different countries. A noticeable trend 
was the generally low use of AS-AQ relative to AL, even 
in countries which recommend this drug in their first-
line policy. A further trend was generally much higher 
estimated access to ACTs in countries with AL first-line 
policies (figure 4). Moreover, in countries with available 
data on Pfmdr1 trends over time, the average mean % of 
RDT+fever cases which received ACT (during the time 
period the Pfmdr1 data were gathered; estimates from 
the Malaria Atlas Project11) was 19% in countries recom-
mending AL alone but only 3% in countries recom-
mending AS-AQ or AL/AS-AQ.
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Figure 3 Selection of Plasmodium falciparum multidrug resistance 1 (Pfmdr1) polymorphisms in 32 locations within countries 
with different first-line artemisinin-based combination therapies (ACT) policies, as shown by the change in the ratio of Pfmdr1 
mutant to wild type frequency/prevalence over time since introduction of ACT policy. Panels show natural log mutant:wild type 
ratios at Pfmdr1 positions 86 (A–C), 184 (D–F) and 1246 (G–I). Areas had (A,D,G): artemether–lumefantrine (AL) policy, (B,E,H) 
artesunate–amodiaquine (AS-AQ) policy or (C,F,I) both AL and AS-AQ policy. Circles indicate the data, coloured by location 
and lines the fitted weighted linear regression at each location (see online supplementary figure S5-7 for the data separately by 
location). The slope on the natural log scale indicates the selection coefficient at each location. Where available, frequencies of 
each allele were used to estimate the slopes (solid lines), or otherwise prevalence data were used (dashed lines – see also the 
Methods section).
In countries with AL policy, there was a slight trend 
that locations with higher estimated AL coverage 
among cases11 (>20%) during the time period when 
Pfmdr1 SNP trends were measured showed more nega-
tive selection of 1246Y although this was not statistically 
significant(figure 4, online supplementary table S1). 
Selection of 86Y and 184F were not associated with AL 
coverage. There were not enough data from countries 
with AS-AQ or AL/AS-AQ policies to analyse associations 
of ACT consumption with selection.
 o
n
 10 Novem
ber 2018 by guest. Protected by copyright.
http://gh.bmj.com/
BM
J G
lob Health: first published as 10.1136/bmjgh-2018-000999 on 19 October 2018. Downloaded from 
Okell LC, et al. BMJ Glob Health 2018;3:e000999. doi:10.1136/bmjgh-2018-000999 7
BMJ Global Health
Figure 4 Consumption of artemisinin-based combination therapies (ACT) and Plasmodium falciparum multidrug resistance 1 
(Pfmdr1) single nucleotide polymorphism (SNP) selection. Panels A–C: The proportion of all antimalarials taken/given which are 
artemether–lumefantrine (AL) (blue), artesunate–amodiaquine (AS-AQ) (red) or ACT of unknown type (grey, may include AL, AS-
AQ or other), according to national first-line policy. Data are either self-reported antimalarial use by caregivers of children aged 
0–5 years recorded in national household surveys (DHS) or market share of ACT type out of all antimalarials sold/prescribed 
as recorded by representative national surveys of public and private dispensing outlets (ACTWatch). Data are shown for all 
countries with any Pfmdr1 data in our review. Legend indicates colours in panels A–C. Panels D–F: estimated AL consumption 
and selection of Pfmdr1 SNPs in countries with AL first-line policies. Selection coefficients for each SNP were estimated in 
locations with at least two measures of SNP frequency/prevalence over time periods spanning at least 3 years. The dashed 
line indicates zero change in frequency. AL consumption is the mean estimated % febrile RDT-positive 0–5 year olds taking 
ACT during the time period over which SNP trends were available for each location, from analysis by Bennett et al,11 assuming 
that all ACTs taken in these countries are the first-line policy, AL. None of the associations between AL consumption and SNP 
selection are statistically significant. Countries are indicated: AO: Angola, BJ: Benin, ET: Ethiopia, KE: Kenya, MZ: Mozambique, 
RW: Rwanda, TZ: Tanzania, UG: Uganda.
Levels of chloroquine consumption among under 5 
year olds (% taking chloroquine out of all those taking 
antimalarials) during the post-ACT period37 were lower 
in the countries with AL policies included in our analysis 
with a mean of 14% vs 28% in countries with AS-AQ or 
AL/AS-AQ policies. There was a slight trend for higher 
chloroquine consumption in areas with lower initial 
1246Y frequencies at the start of the post-ACT data 
(p=0.048). However, chloroquine consumption was not 
associated with rate of selection of any of the SNPs, either 
in univariate or multivariate analysis (online supplemen-
tary table S1). Transmission intensity (estimated slide 
prevalence among 2–10 year olds,42 was lower on average 
in locations within countries recommending AL at 16% 
slide prevalence, compared with 40% in locations with 
AS-AQ or AL/AS-AQ policies. Transmission intensity 
was not associated with rate of selection of any SNPs in 
univariate or multivariate models (online supplementary 
table S1).
Haplotypes and correlations between snPs
To complement the analysis of individual SNPs and 
understand how linkage between Pfmdr1 polymorphisms 
may contribute to selection, we examined correlations 
of the prevalence of the three SNPs in East, West and 
Central Africa as well as haplotype frequencies in a 
subset of locations with available time series. 184F prev-
alence was negatively correlated with 1246Y (p<0.001) 
(figure 5B). The 86Y and 1246Y mutation prevalences 
show a strong positive correlation (p<0.001) whereby 
1246Y was only present at higher levels when 86Y was also 
present at higher prevalence, which occurred predomi-
nantly in East Africa (figure 5C).
A total of 12 locations in eight countries reported 
multiple measures of haplotypes over time (online 
supplementary figure S13). Five countries with haplotype 
data series used AL as the first-line treatment (Comoros, 
Swaziland, Kenya, Tanzania and Uganda). The general 
trend in these locations was a decrease in at least one of 
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Figure 5 Relationship between prevalence of different Plasmodium falciparum multidrug resistance 1 (Pfmdr1) single 
nucleotide polymorphisms (86Y, Y184, 1246Y), measured in the same surveys and coloured by geographical region as in 
figure 2. Here, we show the wild type Y184 prevalence and its relationship with 86Y and 1246Y mutant prevalence in the 
interests of highlighting possible occurrence of the Pfmdr1 YYY haplotype by region (exact haplotype frequencies are not 
known in the majority of surveys due to mixed infections).
the YYY, YFY and YYD haplotypes and a rise in the NFD 
and NYD haplotypes. A different pattern was seen in the 
Comoros, where the YFY haplotype initially dominated in 
2006, followed by a rise in the YFD and YYD haplotypes 
and eventually higher levels of NYD in 2014. Two loca-
tions with available haplotype data, Zanzibar (Tanzania) 
and Madagascar, used AS-AQ as a first-line treatment. In 
both, there was an unexpected increase of the NYD and 
NFD haplotypes after ACT introduction.
dIsCussIon
During the era of chloroquine use against malaria, the 86Y 
and 1246Y mutations in the Pfmdr1 gene were selected12, 
and the 86Y became widespread in Africa. After the 
change in drug policy from chloroquine to ACT, we find 
that the frequency of 86Y declined markedly over the 
next 10 years in most locations with available data. 1246Y 
has declined in countries using AL, while the 184F muta-
tion increased in frequency in many areas. Our analysis 
indicates that countries with first-line AL policies showed 
significantly more rapid decline of 1246Y, and border-
line significant more rapid decline in 86Y, compared 
with countries recommending AS-AQ or AL/AS-AQ as 
first-line policy. Furthermore, within countries recom-
mending AL, there was a non-significant trend towards 
more rapid decline of the 1246Y in countries with higher 
estimated consumption of AL per malaria case (>20% 
coverage). The trends suggest a slight increase in suscep-
tibility of parasites to AS-AQ in countries which have 
implemented AL alone, consistent with trial results.29 
It is unclear whether the different rates of selection of 
SNPs observed in countries recommending AS-AQ or 
AL/AS-AQ were related to AS-AQ itself. An alternative 
explanation was the very low estimated use of ACTs in 
countries with AS-AQ or AL/AS-AQ policies (only 3% of 
cases receiving ACT on average during the time periods 
examined, and a low average recorded use of AS-AQ 
in household surveys).37 Also, the selection pressure 
exerted by AS-AQ may not be simply in one direction, 
since although amodiaquine is thought to select for the 
86Y and 1246Y, there is some in vitro evidence suggesting 
that the artemisinin component selects for the wild type 
genotypes at these positions.48
We identified several other differences in countries 
which recommend AL compared with countries recom-
mending AS-AQ or AL/AS-AQ, which may have also 
driven SNP trends. It is likely that the original choice 
of AL versus AS-AQ for national policy in many coun-
tries was influenced by their levels of amodiaquine and 
chloroquine resistance at the time. In particular, coun-
tries with AS-AQ as a component of their first-line treat-
ment policy were significantly more likely to have lower 
frequencies of the 1246Y mutation at the time of ACT 
introduction. This factor also explains some of the differ-
ence in SNP trends in countries recommending AS-AQ 
or AL/AS-AQ, that is, there was simply less potential for 
1246Y to decline because initial frequencies were so low. 
Initial SNP frequencies were associated with subsequent 
rates of change in frequency for all three mutations, 
which could be due to regression to the mean (locations 
with initial outlier measurements later have more precise 
measures closer to the true value), or due to epidemi-
ological reasons, for example, variations in treatment 
access between populations. That is, countries with high 
use of chloroquine could have selected 86Y and 1246Y to 
high levels, followed by subsequent similarly high use of 
AL leading to a more rapid decline in those SNPs.
The widespread withdrawal of chloroquine across 
Africa is likely to have caused a decline in 86Y and 1246Y 
frequencies independently of ACT introduction, given 
possible fitness costs of these mutations.49–51 This effect 
may explain why the decline was seen even in countries 
recommending AS-AQ. We examined whether countries 
which withdrew chloroquine more quickly after offi-
cially switching to ACT might show more rapid rates of 
decline in these mutations, but we did not find quantita-
tive evidence for this in our analysis. However, there are 
limitations in the estimates of chloroquine consumption 
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(see below). Countries with AS-AQ or AL/AS-AQ policies 
included in our analysis had on average higher chloro-
quine consumption, probably because they had lower 
initial prevalence of 1246Y, and thus better chloroquine 
efficacy.
We focused on separate SNPs in our analysis, due to 
paucity of data on haplotypes, although there is genetic 
linkage between these loci. Our review data suggest that 
the 1246Y has only spread to high levels where the 86Y 
was highly prevalent. SNPs at position 86 and 184 have 
previously been shown to be co-selected,52 although 
here only 86Y selection showed an association with 
ACT policy. Although the limited available haplotype 
data generally confirmed the SNP trends, showing an 
increase in NFD haplotypes in AL countries, the under-
lying dynamics may be more complex (eg, as shown for 
selection after DHA–piperaquine53) and depend on the 
past frequencies of haplotypes as well as importation 
of different haplotypes. Future analysis for example, 
of microsatellite data will elucidate genetic lineages of 
Pfmdr1 haplotypes, while gene editing and phenotype 
testing could clarify whether each of the three loci 
confer changes in drug sensitivity, or rather fitness, or 
are simply co-selected. In addition, sensitivity to AL 
and AS-AQ is associated with mutations in the P. falci-
parum chloroquine resistance transporte (Pfcrt) gene 
and Pfmdr1 copy number variation, which we did not 
consider here.5 Further analysis is required to define 
how mutations in these two genes are co-selected over 
time. Not all research laboratories are equipped to 
measure copy number variation which may mean that 
multiple copies are under-reported in Africa.
Influx of parasites from neighbouring countries is 
likely to influence SNP trends, particularly in lower trans-
mission areas where a higher proportion of parasites are 
imported. AL countries are predominantly in East Africa, 
AS-AQ countries in central Africa and AL/AS-AQ coun-
tries in West Africa, so that it is difficult to distinguish the 
roles of spatial spread and drug pressure. Morris et al54 
and Froberg et al48 studied the potential effect of spatial 
mixing in Zanzibar, Tanzania, where AS-AQ is used as 
first-line treatment, in contrast to mainland Tanzania 
where AL is first -line. Their studies showed reductions 
in prevalence of markers associated with amodiaquine 
resistance in Zanzibar, despite the use of AS-AQ as first-
line treatment for many years (data also included in 
our analysis). Continued use of AL as second line, and 
its potential availability in the private sector could have 
contributed to these trends, but Zanzibar’s current low 
malaria prevalence55 and frequent travel to and from 
the mainland suggest a potential role for spatial spread 
of parasites. Spatial spread of parasites may also explain 
why we did not observe any clear differences in rate of 
selection by transmission intensity setting in the Pfmdr1 
SNP trends either in univariate analysis or after adjusting 
for drug policy or drug consumption. Differences are 
expected based on theoretical56–58 and some empirical 
results,57 but if parasites rapidly diffuse across a large 
enough area, differences between transmission settings 
might be quickly evened out.59
The data and analysis used here have limitations which 
may explain the absence of some expected associations, 
such as have been seen in multicountry standardised 
studies of antibiotic resistance and antibiotic consump-
tion.60 The data on drug consumption from household 
surveys are an excellent resource and give access to stan-
dardised measures across the continent. However, drug 
consumption is self-reported, which may reduce accuracy 
and surveys are relatively infrequent in some locations. 
Furthermore, these measures were from under 5 year 
olds, and adults often tend to use different, cheaper drugs 
like SP.39 We used time since ACT policy introduction as 
a variable in our analysis, but the speed and coverage at 
which ACT policies are implemented varied in different 
countries.36 The presence of substandard or falsified 
ACTs in some countries may also affect SNP trends, but 
there are not sufficiently detailed data over time and in 
enough countries to include this factor in our analysis.61
A large number of Pfmdr1 surveys have been 
conducted, but these are not necessarily representative 
of the continent since they tend to be concentrated in 
particular countries. The measures are also not stan-
dardised, including study populations of different 
ages and source populations (clinical/community), 
which may have different mutation prevalence.62 We 
made the simplistic assumption of constant selection 
of SNPs after introduction of ACT policy, given the 
lack of continuous measures of drug consumption and 
resistance, but could fit most longitudinal Pfmdr1 data 
series reasonably well. We assumed a constant of three 
parasite generations per year. Generation time may 
vary by study setting, for example areas with higher 
overall access to antimalarial treatment may have on 
average shorter infections and generation times.63 This 
parameter is not well characterised but may affect our 
comparison of areas.
Many rich longitudinal datasets in different coun-
tries contributed to the trends analysed here. The most 
detailed data were often from countries with AL policy 
such as Kenya, Tanzania and Mozambique. The original 
publications, as well as noting overall increases in the 
N86 and often the 184F and D1246 when AL was intro-
duced, sometimes reported detailed local information 
such as fluctuations in drug availability, that we did not 
capture since it was not available for most included 
locations. In Kenya, Angola and Guinea-Bissau after AL 
policy introduction, amodiaquine, SP–amodiaquine 
or quinine were reportedly used in some areas during 
periods when AL was not available, which the authors 
suggest may have slowed selection of the NFD haplo-
type.35 36 64–67 Senegal, which had a policy of AL/AS-AQ 
reported that sometimes only one ACT was in use due 
to stock-outs, and that when both were available, AL 
was used more often because it was better tolerated.68 69 
Longitudinal studies in countries using AS-AQ noted 
more stable trends in Pfmdr1 SNP prevalence, which 
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was attributed to ongoing use of alternative antimalar-
ials, selection of wild type N86 and D1246 by the arte-
misinin component and importation of parasites.48 70 71
The trends in Pfmdr1 SNPs at a population level in 
Africa can help to identify how opposing selection 
pressures exerted by these two ACT combinations may 
be harnessed by drug policies to improve treatment 
outcomes. Drug cycling is one proposed option, for 
example countries which have used AL and reduced the 
frequency of the YYY haplotype may consider switching 
to AS-AQ.29 Several countries already recommend both 
AL and AS-AQ as first-line therapy (online supplemen-
tary figure S8), although the optimal proportion of each 
drug provided is unclear, and might depend on relative 
selection strength of each drug and the levels of treat-
ment failure after different drug–genotype combina-
tions.72 A strategy of retreating treatment failures with 
the alternative combination (AL failures with AS-AQ, 
and vice versa) has been proposed.31 In the future, 
enhanced diagnostics are likely to optimise treatment 
choice for each patient dependent on the genotype of 
their infection.73 Clinical trials are also studying the effi-
cacy of sequential treatment with two different ACTs,74 
and triple combination therapy containing an arte-
misinin derivative, lumefantrine and amodiaquine.75 
Given the importance of partner drug effectiveness in 
preventing ACT treatment failure as well as artemisinin 
resistance spread, it will be important to continue and 
expand monitoring of both resistance as well as rates of 
different ACT consumption.
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